PTC Therapeutics
PTCT
352 hedge funds and large institutions have $6.51B invested in PTC Therapeutics in 2026 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 145 increasing their positions, 102 reducing their positions, and 56 closing their positions.
384% more call options, than puts
Call options by funds: $57.5M | Put options by funds: $11.9M
42% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 102
9% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 56
0.07% less ownership
Funds ownership: 115.48% → 115.41% (-0.07%)
0% less funds holding
Funds holding: 353 → 352 (-1)
8% less capital invested
Capital invested by funds: $7.04B → $6.51B (-$534M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$166M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$46.8M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$36.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$35M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$85.7M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$78.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$54.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$52M |
| 5 |
AC
Armistice Capital
New York
|
-$51.5M |
PTCT Hedge Fund Activity: Q1 2026 in Review
352 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2026, worth a combined $6.51B — down 7.6% from $7.04B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new PTCT positions and 56 closed out — a net gain of 5 holders — while 145 added to existing stakes and 102 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $166M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $85.7M sold.
- 352 institutional investors held PTC Therapeutics (PTCT) as of Q1 2026, down from 353 in Q4 2025.
- Funds reported $6.51B of PTC Therapeutics stock for Q1 2026, down 7.6% quarter-over-quarter.
- 61 funds opened new PTC Therapeutics positions in Q1 2026 and 56 closed out, a net change of +5 holders.
- The largest PTC Therapeutics buyer in Q1 2026 was Janus Henderson Group, an estimated $166M added.
- The largest PTC Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $85.7M sold.
Based on aggregated 13F filings for Q1 2026.